Gamboa-Salcedo T, Cardoso-Hernández G, Saucedo-Ramírez OJ, Peña-Alonso YR

Language: Spanish
References: 30
Page: 68-75
PDF size: 180.17 Kb.

ABSTRACT

Introduction. Chronic granulomatous disease (CGD) is an immunodeficiency characterized by a defect of phagocitosis, so initial manifestations are those from the secondary infection. It is an uncommon disease, whose diagnosis is always a challenge.
Case report. The case of a previously healthy boy who came to the hospital with fever of unknowns origin is presented. He was diagnosed with persistent pneumonia that required decortication. Burkholderia cepacia grew from the lung biopsy culture. Because this bacteria has been related to immunodeficient patients, screening for immunodeficiency were performed and the diagnosis of CGD was established.
Conclusion. Immunodeficiency should be ruled out in patients with infections due to B. cepacia.

REFERENCES

1. Berendes H, Bridges RA, Good RA. A fatal granulomatosus of childhood: the clinical study of a new syndrome. Minn Med. 1957; 40: 309-12.

2. Roos D. The genetic basis of chronic granulomatous disease. Immunol Rev. 1994; 138: 121-57.

3. Cos-Padrón Y, Marsán-Suárez V, Sánchez-Segura M, Macías-Abraham C. Enfermedad granulomatosa crónica. Aspectos actuales. Rev Cubana Hematol. 2004; 20: 1-10.

4. Del Río-Chivaldi J, Ávila-Castañón L, Sienra-Monge JJL, del Río-Navarro B. Enfermedad granulomatosa crónica. Reporte de un caso y revisión de la literatura. Rev Alergia Mex. 2003; L: 237-40.

5. Winkelstein JA, Marino MC, Johnston RB, Boyle J, Curnutte J, Gallin JL, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine. 2000; 79: 155-69.

6. Goldblatt D, Thrasher AJ. Chronic granulomatous disease. Clin Exp Immunol. 2000; 122: 1-9.

7. Curnutte JT. Chronic granulomatous disease. The salving of a clinical riddle at the molecular level. Clin Immunol Immunophatol. 1993; 62: 2-15.

8. Walther MM, Malech H, Berman A, Choyke P, Venzon DJ, Linehan WM, et al. The urological manifestations of chronic granulomatous disease. J Urol. 1992; 147: 1314-8.

9. Juárez-Escobar M, Peña-Alonso R, Coria JJ, Gómez-Barreto D. Enfermedad crónica granulomatosa: presentación de un caso y aspectos generales. Enferm Infecc Microbiol Clin. 2003; 23: 50-6.

10. Huang A, Abbasakoor F, Vaisey CJ. Gastrointestinal manifestations of chronic granulomatous disease. Colorectal Dis. 2006; 8: 637-44.

11. Zelazko M, Carneiro-Sampaio M, Cornejo-de Luigi M, García-de Olarte D, Porras-Madrigal O, Berrón-Pérez R, et al. Primary immunodeficiency disease in Latin America: First report from eight countries participating in the LAGID. J Clin Immunol. 1998; 18: 161-6.

12. García-Cruz ML, Camacho R, Ortega-Martell JA, Berrón-Pérez R, Espinosa-Rosales F, Hernández-Bautista V, et al. Registro de inmunodeficiencias primarias en pacientes mexicanos en una institución de tercer nivel: experiencia de 30 años. Alergia Asma Immunol Pediatr. 2002; 11: 48-66.

13. Liese J, Kloos S, Jendrossek V, Petropoulou T, Wintergerst U, Notheis G, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr. 2000; 137: 687-93.

14. Cardoso HG, de Colsa RA, Zepeda OG, Arzate BP, González SN. Manifestaciones clínicas y factores de riesgo para bacteriemia por Burkholderia cepacia en niños. Rev Infect Pediatr. 2007; 80: 92-8.

15. Quie PG. Chronic granulomatous disease of childhood: a saga of discovery and understanding. Pediatr Infect Dis J. 1993; 12: 395-8.

16. Zumia A, James DG. Granulomatous infections: etiology and classification. Clin Infect Dis. 1996; 23: 146-58.

17. Kume A, Dinauer MC. Gene therapy for chronic granulomatous disease. J Lab Clin Med. 2000; 135: 122-8.

18. Margolis DM, Melnick DA, Alling DW, Gallin JL. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990; 162: 723-6.

19. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003; 348: 2416-22.

20. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr. 1994; 125: 998-1003.

21. Ma HR, Mu SC, Yang YH, Chen CM, Chiang BL. Therapeutic effect of interferon-gamma for prevention of severe infection in X-linked chronic granulomatous disease. J Formos Med Assoc. 2003; 102: 189-92.

22. Newburger PE, Ezekowitz RA. Cellular and molecular effects of recombinant interferon gamma in chronic granulomatous disease. Hematol Oncol Clin North Am. 1988; 2: 267-76.

23. International Chronic Granulomatous Disease Cooperative Study Group. A. Phase III study establishing efficacy of recombinant human interferon-gamma for infection prophylaxis in chronic granulomatous disease. N Engl J Med. 1991; 324: 509-16.

24. Roesler J, Koch A, Pörksen G, von Bernuth H, Brenner S, Hahn G, et al. Benefit assessment of preventive medical check-ups in patients suffering from chronic granulomatous disease (CGD). J Eval Clin Pract. 2005; 11: 513-21.

25. Alsultan A, Williams MS, Lubner S, Goldman FD. Chronic granulomatous disease presenting with disseminated intracranial aspergillosis. Pediatr Blood Cancer. 2006; 47: 107-10.

26. Fleisher TA. Primary immune deficiencies: Windows into the immune system. Pediatr Rev. 2006; 10: 363-72.

27. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med. 2000; 343: 1703-13.

28. Hasui M. Chronic granulomatous disease in Japan: incidence and natural history. The Study Group of Phagocyte Disorders of Japan. Pediatr Int. 1999; 41: 589-93.

29. Horowitz ME, Barret AJ, Brown MR, Carter SC, Childs R, Gallin JI, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2000; 344: 881-8.

30. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008; 140: 255-66.